Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DGAT1 | O75907 | 5/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | KLKB1 | P03952 | 1/20 | 0.33 |
| ▸ | NPC1 | O15118 | 1/20 | 0.32 |
| ▸ | CFD | P00746 | 2/20 | 0.32 |
| ▸ | IL1B | P01584 | 2/20 | 0.32 |
| ▸ | P2RX7 | Q99572 | 2/20 | 0.32 |
| ▸ | ADK | P55263 | 1/20 | 0.31 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.30 |
| ▸ | BRD4 | O60885 | 1/20 | 0.30 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20744082 | 0.91 | NPC1 (0.39) | DGAT1MAPTKLKB1NPC1CFD | |
| SCHEMBL30668697 | 0.91 | NPC1 (0.39) | DGAT1MAPTKLKB1NPC1CFD | |
| SCHEMBL16051210 | 0.87 | DGAT1 (0.38) | DGAT1NPC1ALDH1A1SMN1; SMN2 | |
| SCHEMBL21678636 | 0.86 | DGAT1 (0.38) | DGAT1MAPTKLKB1P2RX7ADK | |
| SCHEMBL31070086 | 0.86 | DGAT1 (0.38) | DGAT1MAPTKLKB1P2RX7ADK | |
| SCHEMBL21678363 | 0.85 | DGAT1 (0.33) | DGAT1MAPTKLKB1CFDIL1B | |
| SCHEMBL21678521 | 0.84 | TP53 (0.38) | DGAT1MAPTKLKB1P2RX7SMN1; SMN2 | |
| SCHEMBL31070094 | 0.84 | TP53 (0.38) | DGAT1MAPTKLKB1P2RX7SMN1; SMN2 | |
| SCHEMBL2238226 | 0.83 | DGAT1 (0.34) | DGAT1MAPTKLKB1NPC1ADK | |
| SCHEMBL2696013 | 0.82 | DGAT1 (0.35) | DGAT1MAPTKLKB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110201599-A1 | CDK Modulators | EXELIXIS, INC. (US) | 2011-08-18 | — | — | US | disclosed |
| US-20110201599-A1 | CDK Modulators | EXELIXIS, INC. (US) | 2011-08-18 | — | — | US | disclosed |
| US-20110201599-A1 | CDK Modulators | EXELIXIS, INC. (US) | 2011-08-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110201599-A1 | CDK Modulators | CDK3, CDK1, CDKL1 | DGAT1 3881/4885MAPT 2120/4885KLKB1 2234/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.